Prospectus 5/29/2020 | NWBO Message Board Posts

Northwest Biotherapeutics Inc.

  NWBO website

  •  Registered Members of Investor Village:
    Please make sure you are signed in to your Investor Village account to enjoy the full benefits of our service and avoid the MediaPass paywall. If the MediaPass offer page is blocking you, click the light blue "No thanks, take me back" link on the middle right side of the form to get to our home page where you can sign in by entering your Investor Village User Name and Password. 

     MediaPass subscribers: Please make sure you are logged in to your MediaPass subscription to bypass the paywall. You can do this by clicking the light blue "Already have a MediaPass account? Login here" link on the middle left side of the subscription offer form and then entering the email address and password you used when you first signed up with MediaPass.  

    For assistance call 888-222-7309 or email admin@investorvillage.com

NWBO   /  Message Board  /  Read Message

 

 






Keyword
Subject
Between
and
Rec'd By
Authored By
Minimum Recs
  
Previous Message  Next Message   Post Message   Post a Reply return to message boardtop of board
Msg  13987 of 13994  at  6/28/2020 5:24:36 PM  by

clsm

The following message was updated on 6/28/2020 5:34:14 PM.

 In response to msg 13986 by  Hodag
view thread

Re: Prospectus 5/29/2020

A lot of companies are working on allogeneic CAR-T, CAR-NK and TCR-T products (from healthy donors and/or iPSCs). With these you can produce 100s-1000s of doses in a single run, greatly reduce costs (data from FATE and NKTX back this up) [1], there will be improved consistency between batches, and they may have better activity [2,3]. AUTL will be move their first version forward in Q4 and add two additional transgenes to stop GvH [4] and HvG (rejection).

In terms of (S)AEs (CRS and neurotox) then there are ways to reduce them for hematologic malignancies. GILD is in the clinic [5] and will likely use SGMO's ZFNs to KO a certain gene as well [6].

Refs:
1 https://www.celltherapyjournal.org/article/S1465-3249(19)30003-9/fulltext
2 https://crisprtx.gcs-web.com/static-files/8f11c096-aca7-433b-9e7b-465bc51826d0
3 https://crisprtx.gcs-web.com/static-files/bca61f6d-452c-4523-bc90-99605f616893
4 https://ashpublications.org/blood/article/132/Supplement 1/700/266123/A-Protein-Based-Method-to-Develop-Allogeneic
5 https://www.nature.com/articles/s41591-019-0737-3
6 https://ashpublications.org/blood/article/133/7/697/260575/GM-CSF-inhibition-reduces-cytokine-release


     e-mail to a friend      printer-friendly     add to library      
| More
Recs: 0     Views: 91
Previous Message  Next Message   Post Message   Post a Reply return to message boardtop of board






About Us  •  Contact Us  •  Follow Us on Twitter  •  Members Directory  •  Help Center  •  Advertise
Not a member yet? What are you waiting for? Create Account
Want to contribute? Support InvestorVillage by donating
© 2003-2019 Investorvillage.com. All rights reserved. User Agreement
   
Financial Market Data provided by
.


Loading...